UNSPSC 51111725: Acodazole

This classification denotes an intercalating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M28A9O41G. European Medicines Agency schedules Acodazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05245MIG. Acodazole generally arises in the molecular formula C20H19N5O.

UNSPSC 51111725 Acodazole is a Commodity code that does not align with the recent state and local solicitations tagged under it. The code nominally refers to a single pharmaceutical active ingredient, yet the recent opportunities posted under this code span naloxone procurement, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. State and local governments do not appear to be buying acodazole specifically in recent solicitations; instead, the code has been misapplied to a broader set of pharmaceutical and medical supply procurements that bear no direct relationship to the ingredient itself. Issuing bodies under this code include a county government (Seminole County, Florida), a state health agency (Texas HHS Commission), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota Department of Administration). The scope divergence suggests either tagging error or the code's use as a catch-all for pharmaceutical procurement when more precise codes are unavailable.

Recent activity spans Florida, Texas, and Minnesota-based cooperative procurement. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023, response deadline (note: deadline date appears erroneous in source). The City of Tampa issued ITB 26P00145 on March 25, 2026, for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a March 13, 2026, response deadline; this procurement is sheltered for Small Local Business Enterprises with a 5% bid discount. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor capabilities for direct-to-manufacturer prescription programs. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. No recent opportunities show procurement of acodazole as a specified product, and the code shows little relevant activity for this specific active ingredient in state and local contracting.